March 3, 2026Revista Española de Enfermedades Digestivas0 citations

Long-term use of subcutaneous infliximab biosimilar CT-P13 in patients with inflammatory bowel disease in clinical practice

JHJosé María HuguetHospital General Universitario De Valencia LRLidia Martí RomeroAssociation of Electronic and Information Technologies MBMarta Maia Boscá-WattsHospital Clínico Universitario de Valencia

Key Points

Sustained treatment persistence was observed with subcutaneous infliximab over a three-year period.
Stable disease control was maintained among patients using the biosimilar CT-P13, supporting its effectiveness.
Analysis included real-world findings, emphasizing the practical use of subcutaneous infliximab.
This approach may enhance convenience for patients in long-term inflammatory bowel disease management.

Abstract

Switching from intravenous to subcutaneous infliximab biosimilar CT-P13 was associated with sustained treatment persistence, stable disease control, favorable pharmacokinetics, and good tolerability over 3 years. These real-world findings support SC CT-P13 as a convenient long-term maintenance option in routine clinical practice.

问 AI

Bookmark

View Full Paper